



Central African Republic COVID-19 Preparedness and Response Project (P173832)

WESTERN AND CENTRAL AFRICA | Central African Republic | Health, Nutrition & Population Global Practice | IBRD/IDA | Investment Project Financing | FY 2020 | Seq No: 9 | ARCHIVED on 05-Feb-2024 | ISR59673 |

Implementing Agencies: Central African Republic, Ministry of Health and Population

Key Dates**Key Project Dates**

Bank Approval Date: 20-Apr-2020

Effectiveness Date: 27-Apr-2020

Planned Mid Term Review Date: 03-Mar-2022

Actual Mid-Term Review Date: 02-Mar-2022

Original Closing Date: 30-Jun-2022

Revised Closing Date: 30-Jun-2024

Project Development Objectives

Project Development Objective (from Project Appraisal Document)

To prepare for and respond to the threat posed by COVID-19 in the Central African Republic.

Has the Project Development Objective been changed since Board Approval of the Project Objective?

No

Components Table

Name

Preparedness and Response:(Cost \$31.60 M)
Project Coordination and management:(Cost \$1.40 M)
Contingent Emergency Response Component

Overall Ratings

Name	Previous Rating	Current Rating
Progress towards achievement of PDO	<input type="checkbox"/> Satisfactory	<input type="checkbox"/> Satisfactory
Overall Implementation Progress (IP)	<input type="checkbox"/> Satisfactory	<input type="checkbox"/> Satisfactory
Overall Risk Rating	<input type="checkbox"/> Substantial	<input type="checkbox"/> Substantial

Implementation Status and Key Decisions

COVID-19 project restructuring process was completed in May 2023 followed by revision of the Annual Work Budget Plan in close coordination with GAVI, WHO and UNICEF to include new proposed activities to strengthen the overall national immunization capacity. A memorandum of understanding between UNICEF and the government to purchase 1,468,800 doses of J&J vaccines was signed in April 2023, and all doses were delivered by October 2023, with more than 50 percent used during integrated vaccine mass campaigns which accelerated the implementation of the National Vaccine Deployment Plan with the vaccination coverage of 80 percent as of today.

MPA Program Development Objective



The Program Development Objective is to prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness

Multiphase Programmatic Approach (MPA) Status

Good progress is being made in the implementation of AF-V operations. As of January 15, 2024, the Bank has approved 117 operations (including MPA-V operations) to support vaccine procurement and rollout in 78 countries amounting to \$8.70 billion. Four operations have been approved in the past months including: (i) Senegal AF2 operation for \$15 million financed by a Grant from The Global Finance Facility (GFF) approved on June 30, 2023; (ii) a Second AF (IDA Grant of \$1.50 million) approved on August 31, 2023 for Sao Tome and Principe, (iii) a Grant of \$3.94 approved for Chad on July 23, 2023; and (iv) Zimbabwe AF2 operation for \$15 million financed by a Grant from the GFF approved on December 7, 2023. 121 operations had been approved amounting to \$10 billion, but partial cancellations have been processed in the past months under several operations. In addition, four operations were cancelled: (i) Costa Rica loan (\$120 million), (ii) Peru loan (\$500 million), (iii) Gabon loan (\$12 million), which loan agreement lapsed, and (iv) Philippines AF2 loan of \$300 million. The Afghanistan operation commitment of \$113 million was reduced to \$60 million. Of the 117 approved operations: (i) 67 are in Africa – 32 in AFE and 35 in AFW; (ii) 10 in East Asia and the Pacific; (iii) 11 in Europe and Central Asia; (iv) 11 in Latin America and the Caribbean; (v) 9 in Middle East and North Africa; and (vi) 9 in South Asia. The 117 operations approved, include 6 operations that involved restructuring of parent projects (Bhutan, Cameroon, North Macedonia, Philippines, and Pakistan) and in the case of Lebanon, restructuring of the Health Resilience Project.

Thirty-two (32) operations are being implemented in Fragile and Conflict-affected situations. IDA represents 45 percent and IBRD 55 percent of disbursements. **Total disbursements under these projects as of January 15, 2024, amount to US\$6.46 billion or 74 percent of overall commitments.** Disbursements under MPA-V operations are included in this total while disbursements under the six restructured projects are counted under parent projects. With less than planned demand for IDA/IBRD funds for vaccine procurement because, *inter alia*, over supply of vaccines from donations from various sources, several projects have been/are being restructured and more will need to be restructured to reallocate funds or partially cancel funds allocated to procurement of COVID-19 vaccines and deployment. **Guidance was issued under an Email from Juan Pablo Uribe of July 7, 2023, which provided direction for the use of undisbursed funds under COVID-19 operations.**

Four (4) operations are fully disbursed (Argentina, Indonesia, Sri Lanka AF-V 1, and Ukraine AF-V 3). Fifty-three (53) operations or 45 percent of operations approved have disbursed over 70 percent of their commitments. Out of the 53, twenty-two (22) operations have disbursed 90+ percent. Ninety-eight (98) operations or 84 percent of total operations approved are disbursing. EAP has the highest percentage of disbursements at 94 percent, followed by ECA at 87 percent, LAC at 84 percent, SAR at 80 percent, MNA at 79 percent, AFE at 61 percent, and AFW at 59 percent.

Retroactive Financing (RF) represents 37 percent of overall commitments. ECA has the highest level of RF at 74 percent, followed by SAR at 68 percent, LAC at 59 percent, MNA and AFE at 29 percent and AFW at 13 percent. Disbursements to UN agencies represent 22 percent of overall disbursements, while Direct Payment represents 16 percent of disbursements.

As with the COVID-19 MPA operations, streamlined procedures, delegated approval, wide use of Bank Facilitated Procurement (BFP), coupled with flexible project design, and intensified efforts from counterparts and Bank staff have contributed to the rapid design, processing, and implementation of the AF-V operations.

Risks

Systematic Operations Risk-rating Tool



Risk Category	Rating at Approval	Previous Rating	Current Rating
Political and Governance	High	High	High
Macroeconomic	High	Substantial	Substantial
Sector Strategies and Policies	Substantial	Substantial	Substantial
Technical Design of Project or Program	High	Substantial	Substantial
Institutional Capacity for Implementation and Sustainability	High	Substantial	Substantial
Fiduciary	High	High	Substantial
Environment and Social	Substantial	Substantial	Substantial
Stakeholders	Substantial	Substantial	Substantial
Other	--	--	--
Overall	High	Substantial	Substantial

Results

PDO Indicators by Objectives / Outcomes

To prepare for and respond to the threat posed by COVID-19 in the Central African Republic.				
▶ Health staff trained in infection prevention per MOH-approved protocols (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	516.00	516.00	500.00
Date	27-Apr-2020	16-Jun-2023	16-Jun-2023	30-Jun-2024
Comments:	Exceeded end target for original financing phase. This indicator is no longer tracked during AF phase.			
□ Health staff trained in infection prevention per MOH-approved protocols (Number, Custom) (Number, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	--	516.00	500.00
Date	27-Apr-2020	--	14-Dec-2023	30-Jun-2024
▶ Personal protective equipment (PPE) kit (masks, face shield, gloves, gown) delivered to targeted health facilities (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	17,250.00	17,250.00	9,000.00
Date	27-Apr-2020	16-Jun-2023	16-Jun-2023	30-Jun-2024
Comments:	Exceeded end target under the original financing phase by almost two-fold. This indicator is no longer tracked under the AF.			



<input type="checkbox"/> Personal protective equipment (PPE) kit (masks, face shield, gloves, gown) delivered to targeted health facilities (Number, Custom) (Number, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	--	17,250.00	9,000.00
Date	27-Apr-2020	--	14-Dec-2023	30-Jun-2024
► COVID-19 risk communication messages broadcasted to communities (number of days) (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	474.00	474.00	90.00
Date	27-Apr-2020	16-Jun-2023	16-Jun-2023	30-Jun-2024
Comments:	Mobile COVID-19 voice messages began being transmitted on April 27, 2020, and has been active since then. The support is no longer continued under the AF phase.			
<input type="checkbox"/> COVID-19 risk communication messages broadcasted to communities (number of days) (Number, Custom) (Number, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	--	474.00	90.00
Date	27-Apr-2020	--	14-Dec-2023	30-Jun-2024
► Population vaccinated (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	13.00	50.00	80.00	70.00
Date	08-Feb-2022	16-Jun-2023	14-Dec-2023	30-Jun-2024
Comments:	Reflects percentage of population receiving first dose of the overall target population. The end target has been revised to reflect the third National Vaccine Deployment Plan updated in November 2022 which sets the population coverage target at 70 percent from the initial 52 percent under PNVD I. The end target has surpassed.			
<input type="checkbox"/> Population vaccinated (Percentage, Custom) (Percentage, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	13.00	--	80.00	70.00
Date	08-Feb-2022	--	14-Dec-2023	30-Jun-2024
► Proportion of women among those vaccinated (Percentage, Custom Supplement) (Percentage, Custom)				



	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	40.00	--	43.00	50.00
Date	08-Feb-2022	--	14-Dec-2023	30-Jun-2024

Intermediate Results Indicators by Components

Component 1: Preparedness and response				
► Additional patient "beds" made available in designated care centers and hospitals (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	73.00	73.00	70.00
Date	27-Apr-2020	16-Jun-2023	16-Jun-2023	30-Jun-2024
Comments:	Exceeded end target under the original financing phase. This activity is no longer supported under AF phase and indicator no longer tracked.			
□ Additional patient "beds" made available in designated care centers and hospitals (Number, Custom) (Number, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	--	73.00	70.00
Date	27-Apr-2020	--	14-Dec-2023	30-Jun-2024
► Laboratories with trained staff and consumables for collecting COVID-19 samples and transporting to Pasteur Institute laboratory (IBP) (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	1.00	91.00	91.00	15.00
Date	27-Apr-2020	16-Jun-2023	16-Jun-2023	30-Jun-2024
Comments:	Initial target was set at 15 assuming only district hospital laboratories. However, a large number of primary level health facilities staff in CAR where they have small laboratories were also trained and are now also collecting COVID-19 samples. The actuals include these facilities. The indicator is no longer tracked under the AF.			
□ Laboratories with trained staff and consumables for collecting COVID-19 samples and transporting to Pasteur Institute laboratory (IBP) (Number, Custom) (Number, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	1.00	--	91.00	15.00
Date	27-Apr-2020	--	14-Dec-2023	30-Jun-2024



► Risk communication strategy developed and disseminated (Yes/No, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	No	Yes	Yes	Yes
Date	27-Apr-2020	16-Jun-2023	16-Jun-2023	30-Jun-2024
Comments:	Strategy has been elaborated and the govt is starting to use it in parts.			
 <input type="checkbox"/> Risk communication strategy developed and disseminated (Yes/No, Custom) (Yes/No, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	No	--	Yes	Yes
Date	27-Apr-2020	--	14-Dec-2023	30-Jun-2024
► Targeted facilities that have received selected drugs required to respond to the surge in patients due to COVID-19 (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	100.00	100.00	90.00
Date	27-Apr-2020	30-Dec-2022	30-Dec-2022	30-Jun-2022
Comments:	All treatment centers (4 in Bangui and 32 in the rest of the country) have received medication by August 2021. The number of treatment centers increased, where in all centers, selected medication to care for the COVID19 patients were supplied: July 2020: 9 out of 9 health facilities; January 2021: 15 out of 15 health facilities; August 2021: 36 out of 36 health facilities.			
 <input type="checkbox"/> Targeted facilities that have received selected drugs required to respond to the surge in patients due to COVID-19 (Percentage, Custom) (Percentage, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	--	100.00	90.00
Date	27-Apr-2020	--	14-Dec-2023	30-Jun-2024
► Targeted communities informed on hygiene behavior (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	100.00	100.00	90.00
Date	27-Apr-2020	16-Jun-2023	16-Jun-2023	30-Jun-2024
Comments:	Hygiene promotion activities were organized at the health facility and community levels in the country. Over 250,000 soaps were distributed, in addition to hygiene kits, masks and food stamps, along with hygiene sanitation campaigns with strong community sensitization of COVID19 risk and prevention. Provision and treatment of potable water was also realized in 10 districts in the country. As this activity will continue under the AF, the end target date will be extended.			
 <input type="checkbox"/> Targeted communities informed on hygiene behavior (Percentage, Custom) (Percentage, Custom Breakdown)				



	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	--	100.00	90.00
Date	27-Apr-2020	--	14-Dec-2023	30-Jun-2024
► Doses of COVID-19 vaccines administered as a percentage of doses received (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	35.00	91.00	91.00	60.00
Date	25-Feb-2022	16-Jun-2023	16-Jun-2023	30-Jun-2024
□ Doses of COVID-19 vaccines administered as a percentage of doses received (Percentage, Custom) (Percentage, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	35.00	--	91.00	60.00
Date	25-Feb-2022	--	14-Dec-2023	30-Jun-2024
► Share of vaccinators who are female (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	3.00	38.00	38.00	30.00
Date	31-Jan-2022	16-Jun-2023	16-Jun-2023	30-Jun-2024
□ Share of vaccinators who are female (Percentage, Custom) (Percentage, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	3.00	--	38.00	30.00
Date	31-Jan-2022	--	14-Dec-2023	30-Jun-2024
► Districts in which the vaccination deployment strategy targets areas where women congregate (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	35.00	35.00	25.00
Date	25-Feb-2022	16-Jun-2023	16-Jun-2023	30-Jun-2024
□ Districts in which the vaccination deployment strategy targets areas where women congregate (Number, Custom) (Number, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	--	35.00	25.00



Date	25-Feb-2022	--	14-Dec-2023	30-Jun-2024
► Targeted sites where solar-powered cold chain equipment has been installed and functional (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	76.00	76.00	90.00
Date	25-Feb-2022	16-Jun-2023	16-Jun-2023	30-Jun-2024
Comments:	To align with the NVDP III targets, this indicator target will be revised to reach 90 percent coverage in target sites.			
□ Targeted sites where solar-powered cold chain equipment has been installed and functional (Percentage, Custom (Percentage, Custom Breakdown))				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	--	76.00	70.00
Date	25-Feb-2022	--	14-Dec-2023	30-Jun-2024
► Districts reached by gender-sensitive messages/materials disseminated of public communications and advocacy on COVID-19 vaccination (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	35.00	35.00	25.00
Date	25-Feb-2022	16-Jun-2023	16-Jun-2023	30-Jun-2024
□ Districts reached by gender-sensitive messages/materials disseminated of public communications and advocacy on COVID-19 vaccination (Number, Custom) (Number, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	--	35.00	25.00
Date	25-Feb-2022	--	14-Dec-2023	30-Jun-2024
► Districts with community engagement plan implemented for increasing demand for COVID-19 vaccines by the population (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	35.00	35.00	25.00
Date	25-Feb-2022	16-Jun-2023	16-Jun-2023	30-Jun-2024
□ Districts with community engagement plan implemented for increasing demand for COVID-19 vaccines by the population (Number, Custom) (Number, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	--	35.00	25.00



Date	25-Feb-2022	--	14-Dec-2023	30-Jun-2024
► Districts with a mobile or out-reach facility to administer vaccines (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	35.00	35.00	25.00
Date	25-Feb-2022	16-Jun-2023	16-Jun-2023	30-Jun-2024
□ Districts with a mobile or out-reach facility to administer vaccines (Number, Custom) (Number, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	--	35.00	25.00
Date	25-Feb-2022	--	14-Dec-2023	30-Jun-2024
► Consultation workshops with citizen groups and the media to overcome vaccine hesitancy and enable equitable access to vaccination services (per year) (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	2.00
Date	25-Feb-2022	16-Jun-2023	16-Jun-2023	30-Jun-2024
Comments:	Feedback received during these consultations will be used to inform and adjust activities aiming at overcoming vaccine hesitancy and enabling equitable access to vaccination services. As the Ministry obtains feedback from these consultation processes, adjustments of the content of the activities, communication materials or any other adjustments will be made to incorporate the feedback.			
□ Consultation workshops with citizen groups and the media to overcome vaccine hesitancy and enable equitable access to vaccination services (per year) (Number, Custom) (Number, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	--	1.00	2.00
Date	25-Feb-2022	--	14-Dec-2023	30-Jun-2024

Component 2: Project Implementation, Monitoring and Supervision				
► M&E system established to monitor COVID-19 preparedness and response (Yes/No, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	No	Yes	Yes	Yes
Date	27-Apr-2020	16-Jun-2023	16-Jun-2023	30-Jun-2024
Comments:	Surveillance data on COVID19 cases are collected and reports are disseminated through the Emergency response committee (COUSP) of the Ministry of Health and WHO. So a surveillance system is operating (which started before Project effectiveness), but this is the surveillance of COVID-19 itself, and not a more			



comprehensive Monitoring & Evaluation of overall preparedness and response. There are two initiatives underway to put in place systems for disease surveillance overall, which are not yet completed.				
<input type="checkbox"/> M&E system established to monitor COVID-19 preparedness and response (Yes/No, Custom) (Yes/No, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	No	--	Yes	Yes
Date	27-Apr-2020	--	14-Dec-2023	30-Jun-2024
► Standard operational procedures (SOP) for collection and disposal of medical waste developed and shared with relevant stakeholders (Yes/No, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	No	Yes	Yes	Yes
Date	31-Jan-2022	16-Jun-2023	16-Jun-2023	30-Jun-2024
<input type="checkbox"/> Standard operational procedures (SOP) for collection and disposal of medical waste developed and shared with relevant stakeholders (Yes/No, Custom) (Yes/No, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	No	--	Yes	Yes
Date	31-Jan-2022	--	14-Dec-2023	30-Jun-2024

Performance-Based Conditions

Data on Financial Performance


Disbursements (by loan)

Project	Loan/Credit/TF	Status	Currency	Original	Revised	Cancelled	Disbursed	Undisbursed	% Disbursed
P173832	IDA-D6170	Effective	USD	7.50	7.50	0.00	7.66	0.00	100%
P173832	IDA-D9790	Effective	USD	25.50	25.50	0.00	19.09	5.20	79%

Key Dates (by loan)

Project	Loan/Credit/TF	Status	Approval Date	Signing Date	Effectiveness Date	Orig. Closing Date	Rev. Closing Date
P173832	IDA-D6170	Effective	20-Apr-2020	22-Apr-2020	27-Apr-2020	30-Jun-2022	30-Jun-2024
P173832	IDA-D9790	Effective	25-Feb-2022	09-Mar-2022	05-May-2022	30-Jun-2024	30-Jun-2024

Cumulative Disbursements



Restructuring History

Level 2 Approved on 16-May-2023

Related Project(s)

P177554-Central African Republic COVID19 AF Vaccine Deployment ,P177618-Central African Republic COVID-19 Preparedness & Response Additional Financing